Hit Identification
Hit Identification is a drug discovery process in which biologically active compounds are initially detected from screening assays, distinguished from related processes by its focus on the primary recognition of low-affinity or low-potency compounds that demonstrate specific activity against a target of interest.
88
Publications
6.5K
Citations
460
Authors
167
Institutions
Publications per year
2017–2026
29
Parents
88
Target identification using drug affinity responsive target stability (DARTS)
Brett Lomenick, Rui Hao, Nao Jonai et al. · Proceedings of the National Academy of Sciences · 2009 · 1.1K citations · Full text
HIT: linking herbal active ingredients to targets
Huan Ye, Lin Ye, Hong‐Yo Kang et al. · Nucleic Acids Research · 2010 · 342 citations · Full text
1–5 of 88
460
University of California, Los Angeles, United States
2 publications · 1.3K citations
2
h-index
2
h-index
Genomics Institute of the Novartis Research Foundation, United States
2 publications · 58 citations
2
h-index
2
h-index
2
h-index
1–5 of 460
167
Novartis (Switzerland)
Basel, Switzerland
3 h-index
19 publications
1.1K citations
Bayer (Germany)
Leverkusen, Germany
2 h-index
10 publications
1K citations
University of North Carolina at Chapel Hill
Chapel Hill, United States
2 h-index
4 publications
770 citations
Merck & Co., Inc., Rahway, NJ, USA (United States)
Rahway, United States
2 h-index
15 publications
1.3K citations
Harvard University
Cambridge, United States
2 h-index
2 publications
1.1K citations
University of Bonn
Bonn, Germany
2 h-index
5 publications
470 citations

McGill University
Montreal, Canada
2 h-index
8 publications
1.3K citations
Alzheimer’s Research UK
Cambridge, United Kingdom
2 h-index
5 publications
288 citations
1–8 of 167
14 publications · 998 citations
13
h-index
JCIM · 11 publications · 642 citations
11
h-index
4 publications · 634 citations
4
h-index
Book series · 3 publications · 65 citations
3
h-index
2 publications · 86 citations
2
h-index
1–5